glp-1 and gip/glp-1 receptor agonists Dual agonists: New advances for treating type-2 diabetes GIP and GLP‐1, the two

PF-07976016 - oral GIPR antagonist Phase 2

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

Learn about the benefits of GLP-1 weight loss medications and how they work to support weight management effectively.

The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.

Pharmacovigilance analyses identified disproportionate reporting signals for dyspnoea and asthma-like events, particularly with exenatide, using the reporting odds ratio (ROR 2.14, 95% CI 1.882.43